Anson Funds Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Anson Funds Management’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-30,000	Closed	-$190K	–	260
2022 Q4	$190K	Buy	+30,000	New	+$166K	0.03%	199

Anson Funds Management's FSTX Position: Q2 2022 in Review

Anson Funds Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q2 2022, closing a stake of 185,261 shares — an estimated $658K sold.

Anson Funds Management first reported a position in FSTX in Q4 2021 and held it in 2 quarters. The position peaked at $1.55M in Q4 2021. 53 funds tracked by Wall St. Rank hold FSTX as of Q2 2022.

Anson Funds Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Anson Funds Management sold 185,261 F-star Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $658K.
Anson Funds Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
Anson Funds Management's F-star Therapeutics, Inc. Common Stock position peaked at $1.55M in Q4 2021.
53 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Anson Funds Management's 13F filing for Q2 2022, filed 15 Aug 2022.